

DAFTAR PUSTAKA

- Abraldes, JG., Albillos, A., Bañares, R., Turnes, J., González, R., García-Pagán, JC., *et al.*, 2009. Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial. *Gastroenterology*, 136(5): 1651-8.
- Abraldes, JG., Villanueva, C., Aracil, C., Turnes, J., Hernandez-Guerra, M., Genesca, J., *et al.* 2016. Addition of simvastatin to standard therapy for the prevention of variceal rebleeding does not reduce rebleeding but increases survival in patients with cirrhosis. *Gastroenterology*, 150 : 1160–1170.
- Akçiçek, F., Ok, E., Duman, S., Kürsad, S., Unsal, A., Alev, M., *et al.* 1996. Lipid-lowering effects of simvastatin and gemfibrozil in CAPD patients: a prospective cross-over study. *Adv Perit Dial.*, 12: 261-5.
- Bataller, R., Brenner, D. 2005. Liver Fibrosis. *The Journal of Clinical Investigation*. 115 (2): 209 - 18
- Bayupurnama, P., Neneng, R., Sutanto M. dan Siti, N. 2009. C-Reactive Protein Level in Decompensated Liver Cirrhosis and Its Correlation with Serum Alanine Aminotransferase and Albumin Levels. *The Internet Journal of Gastroenterology*. 9(2):1-3
- Blei, A.T., dan J. Cordoba. 2001. Practice Guidelines : Hepatic Encephalopathy. *The American Journal of Gastroenterology*. 96 (7) : 1967 - 76
- Botta, F., Giannini, E., Romagnoli, P. dan A. Fasoli. 2003. MELD scoring system is useful for predicting prognosis in patients with liver cirrhosis and is correlated with residual liver function. *Gut*. 52 : 134 - 9.
- Bourcier, T., Libby, P. 2000. HMG CoA reductase inhibitors reduce plasminogen activator inhibitor-1 expression by human vascular smooth muscle and endothelial cells. *Arterioscler. Thromb. Vasc. Biol.* 20: 556–62.
- Canbay, A., Friedman, S., Gores, G.J. 2004. Apoptosis: the nexus of liver injury and fibrosis. *Hepatology*, 39: 273-78.
- Canbay, A., Higuchi, H., Bronk, SF., Taniai, M., Sebo, TJ., Gores, G.J. 2002. Fas enhances fibrogenesis in the bile duct ligated mouse: a link between apoptosis and fibrosis. *Gastroenterology*, 123: 1323-30.
- Cholongitas, E., Papatheodoridis M., Vangeli, M. 2005. Systematic review : the model for end-stage liver disease – should it replace Child Pugh’s classification for assesing prognosis in cirrhosis?. *Alinment Pharmacol.* 22 : 1079 - 89

- Cohen-Naftaly, M., Friedman, SL. 2011. Current status of novel antifibrotic therapies in patients with chronic liver disease. *Ther Adv Gastroenterol.* 4(6): 391-417.
- Dahlan, MS. 2009. Besar sampel dan cara pengambilan sampel dalam penelitian kedokteran dan kesehatan. Salemba Medika: Jakarta.
- D'Amico, G., Garcia- Tsao, G. dan Pagliaro, L. 2006. Natural history and prognostic indicators of survival in cirrhosis: A systematic review of 118 studies. *Journal of Hepatology.* 44 (10) : 217 -31
- Dancygier, H. 2010. Liver Cirrhosis. Principles and Practice of Hepatobiliary Diseases. *Clinical Hepatology.* 1 : 157 - 9
- Dancygier, H. 2010. Clinical scoring systems. *Clinical Hepatology.* 1 : 289-90.
- Dietrich, CF., 2010. Ultrasonography. *Clinical Hepatology.* 15 (2): 359-404.
- Durand, F. dan Dominique, V. 2005. Assesment of the prognosis of cirrhosis : Child Pugh vs MELD. *J. Hepatol* 42 : Suppl (1) : 100-7
- Fernández, M., Semela, D., Bruix, J., Colle, I., Pinzani, M., Bosch, J. 2009. Angiogenesis in liver disease. *J Hepatol*, 50: 604–20
- Flores, PP., Soldan, M., Rezend, GF. 2015. Cirrhotic portal hypertenson : new insight in an old syndrome. *Revista Saude e Pesquisa*, 8(2):389-97.
- Foucher, J., Chanteloup, E., Vergniol, J., Castera, L., Le Bail, B., Adhoute, X., *et al.*, 2006. Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study. *Gut*, 55: 403–8.
- Friedman, SL. 2008. Mechanisms of hepatic fibrogenesis. *Gastroenterology*, 134: 1655-69.
- Friedmann, S. 2003. Liver Fibrosis-from bench to bedside. *Journal Of Hepatology*, 38: 38-53.
- García-Pagán, JC., Gracia-Sancho, J., Bosch, J. 2012. Functional aspects on the pathophysiology of portal hypertension in cirrhosis. *J Hepatol*, 57: 458–61.
- Garcia-Tsao G., Lim J., Monto A., Yee H., Durfee J., Dieperink E., *et al.* 2009. Management and Treatment of Patients With Cirrhosis and Portal Hypertension: Recommendations From the Department of Veterans

- Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program. *Am J Gastroenterol*, 104: 1802–1829.
- Gewurz, H., Mold, C., Siegel, J., Fiedel, B. 1982. C-reactive protein and the acute phase response. *Adv Intern Med*. 27:345–72.
- Hiedelbaugh, J. J., dan M. Sherbondy. 2006. Cirrhosis and Chronic Liver Failure : Part. II. Complication and Treatment. *Am Fam P*. 74 (5) : 767 - 76
- Imamura, M., Ogawa, T., Sasaguri, Y., Chayama, K., Ueno, H. 2005. Suppression of macrophage infiltration inhibits activation of hepatic stellate cells and liver fibrogenesis in rats. *Gastroenterology*. 128: 138-46.
- Ito, D., Ito, O., Mori, N., Muroya, Y, Cao, PY., Takashima, K., *et al.* 2010. Atorvastatin upregulates nitric oxide synthases with Rho-kinase inhibition and Akt activation in the kidney of spontaneously hypertensive rats. *Journal Hypertensi*, 28(11): 2278-88.
- Janicko, M., Drazilova S., Pella, D., Fedacko, J., Jarcuska, P. 2016. Pleiotropic effect of statins in the disease of the liver. *World J Gastroenterol*, 22(27): 209 - 15
- Jones, PH., Davidson, MH., Stein, EA., Bays, HE., McKenney, JM., Miller, E., *et al.* 2003. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). *The American Journal of Cardiology*. 93: 152–160.
- Jones, SP., Gibson, MF., Rimmer, DM., Gibson, TM., Sharp, BR., Lefer, DJ. 2002. Direct vascular and cardioprotective effects of rosuvastatin, a new HMG-COA reductase inhibitor. *J Am Coll Cardiol*. 40: 1172–8.
- Kamath, P.S., Wiesner, R. H., Malinchoc, M., Kremers, W., dan T.M. Therneau. 2001. A Model to Predict Survival in Patients With End-Stage Liver Disease. *Hepatology*; 33 : 464-470.
- Katzung, BG. 2002. Farmakologi Dasar dan Klinik, edisi II. Salemba Medika. Jakarta : 671-678.
- Kusumobroto HO. 2007. Sirosis Hati. *In: S. Ali, A. Nurul, A. L. Laurentius, et al. (Ed.) Buku Ajar Ilmu Penyakit Hati*. Jaya Abadi.
- Laufs, U., Endres, M., Stagliano, N., Sepideh, A., Dao-Shan, C., Shui-Xiang, Y., *et al.* 2000. Neuroprotection mediated by changes in the endothelial actin cytoskeleton. *J. Clin. Invest.* 106: 15–24.

- Laufs, U., Gertz, K., Huang, P., Nickenig, G., Bohm, M., Dirnagl, U., *et al.* 2000. Atorvastatin Upregulates Type III Nitric Oxide Synthase in Thrombocytes, Decreases Platelet Activation, and Protects From Cerebral Ischemia in Normocholesterolemic Mice. *Stroke AHA Journals*. 31: 2437-49.
- Laufs, U., La Fata, V., Liao, JK. 1997. Inhibition of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase blocks hypoxia-mediated down-regulation of endothelial nitric oxide synthase. *J. Biol. Chem.* 272: 31725–29.
- Laufs, U., Liao, JK. 1998. Post-transcriptional regulation of endothelial nitric oxide synthase mrna stability by Rho GTPase. *J. Biol. Chem.* 273: 24266–71.
- Laufs, U., Gertz, K., Huang, P., Nickenig, G., Bohm, M., Dirnagl, U., *et al.* 2000. Atorvastatin Upregulates Type III Nitric Oxide Synthase in Thrombocytes, Decreases Platelet Activation, and Protects From Cerebral Ischemia in Normocholesterolemic Mice. *Stroke AHA Journals*, 31: 2437-49.
- Laufs, U., Gertz, K., Dirnagl, U., Bohm, M., Nickenig, G., Endres, M. 2002. Rosuvastatin, a new HMG-CoA reductase inhibitor, upregulates endothelial nitric. *Brain research*. 942 (1-2) : 23 - 30
- Liao, JK. 2002. Isoprenoids as mediators of the biological effects of statin. *J Clin Invest*, 110: 285–8.
- Lochs, H., Plauth, M. 1999. Liver cirrhosis: rationale and modalities for nutritional support--the European Society of Parenteral and Enteral Nutrition consensus and beyond. *Curr Opin Clin Nutr Metab Care*, 4:345-49.
- Malinchoc, M, Kamath, P.S., Gordon, F.D. dan C.J. Peine. 2000. A Model to Predict Poor Survival in Patients Undergoing Transjugular Intrahepatic Portosystemic Shunts. *Hepatology*. 31 (4): 313 - 20
- Mantovani A, Garlanda C, Doni A, Bottazzi B. 2008. "Pentraxins in innate immunity: from C-reactive protein to the long pentraxin PTX3". *Pubmed*. 28 (1) : 1-
- Mason, JC. 2003. Statins and their role in vascular protection. *Clinical Science*. 105:251–66.
- Mason, RP., Corbalan, JJ., Jacob, RF., Dawoud, H., Malinski, T. 2015. Atorvastatin enhanced nitric oxide release and reduced blood pressure, nitrooxidative stress and rantes levels in hypertensive rats with diabetes. *Journal Of Physiology And Pharmacology*. 66 (1): 65-72.

- McGirt, MJ., Lynch, JR., Parra, A., Sheng, H., Pearlstein, RD., Laskowitz, DT., *et al.* 2002. Simvastatin increases endothelial nitric oxide synthase and ameliorates cerebral vasospasm resulting from subarachnoid hemorrhage. *Stroke*, 33: 2950-6.
- Mehdi, H., Shishehbor,, Halder, H., Shetha, R. Des 1st 2002. Statin promote anti inflammatory effect. Department of public health and biostatistics northeastern Ohio Univesities College of Medicine.
- Nangle, MR., Cotter, MA., Cameron, NE. 2003. Effects of rosuvastatin on nitric oxide-dependent function in aorta and corpus cavernosum of diabetic mice : relationship to cholesterol biosynthesis pathway inhibition and lipid lowering. *Diabetes*, 52: 2396–2402.
- Nurdjanah S. 2009. Sirosis Hati. In: A. W. Sudoyo, B. Setiyohadi, I. Alwi, *et al.* (eds) *Buku Ajar Ilmu Penyakit Dalam*. Edisi V Jilid I, Jakarta: *Interna Publishing*: 668-73.
- Nurdjanah S. 2014. Sirosis Hati. In: A. W. Sudoyo, B. Setiyohadi, I. Alwi, *et al.* (eds) *Buku Ajar Ilmu Penyakit Dalam*. Edisi VI Jilid II, Jakarta: *Interna Publishing*: 1978-83.
- Sieghart 2012 Single Determination of C-Reactive Protein at the Time of Diagnosis Predicts Long-Term Outcome of Patients With Hepatocellular Carcinoma. Official journal of the american association for the study of liver disease 2224-223
- Ok young park, soo hang kim, young keun ahn, nam sik yun, ju han kim, chonnam medical journal.vol 44 no 1 13-16. department of internal medicine, college of medicine seonam univerci.y.namwon.march 19.2008
- Pederson, TR.,Tobert, JA. 2004. Simvastatin : a review. *Expert Opin Pharmacother*, 5(12), 2583–96.
- Pepys, MB; Hirschfield, GM. 2003. "C-reactive protein: a critical update". *J Clin Invest*. 112 (2) : 299
- Perz, JF., Armstrong, GL., Farrington, LA., Hutin, YJF., Bell, BP. 2006. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. *Journal of Hepatology*. 45: 529-30.

- Price, S., Wilson, L. 1994. *Patofisiologi Konsep Klinis Proses-Proses Penyakit*. Jakarta : EGC
- Pugh, RN., Murray-Lyon, IM., Dawson, JL., Pietroni, MC., Williams, R. 1973. Transection of the oesophagus for bleeding oesophageal varices. *The British journal of surgery*, 60 (8), 646–9.
- Rajamannan, NM., Subramaniam, M., Stock, SR., Stone, NJ., Springett, M., Ignatiev, KI., *et al.* 2005. Atorvastatin inhibits calcification and enhances nitric oxide synthase production in the hypercholesterolaemic aortic valve. *Heart Journal*, 91: 806–10.
- Rendon, A.R., Gonzalez J.A, Compean, D.C., Maldonado-Garza, HJ., Garza-Galindo, AA., 2008. Model for end stage of liver disease is better than the Child-Pugh score for predicting in-hospital 53 mortality related to esophageal variceal bleeding. *Annals of Hepatology*. 7 (3): 230-4
- Rockey, D., C., dan Friedman S.C. 2006. Hepatic Fibrosis and Cirrhosis in Zakim and Boyer's Hepatology (Fifth Edition). *Elsevier*: 87-103
- Rossoni, LV., Wareing, M., Wenceslau, CF., Al-Abri, M., Cobb, C., Austin, C. 2011. Acute simvastatin increases endothelial nitric oxide synthase phosphorylation via AMP-activated protein kinase and reduces contractility of isolated rat mesenteric resistance arteries. *Clinical Science*. 121: 449–58.
- Samada, M., dan J. C. Hernandez. 2012. Prognostic Factors for Survival in Patients with Liver Cirrhosis *dalam* Abdeldayem, H., (Ed) *Liver Transplantation-Basic Issues* :125-38
- Schomerus, H dan W. Hamster. 1998. Neuropsychological aspects of portalsystemicencephalopathy. *Metab Brain Dis*. 13: 361–77.
- Schierwagen, R., Erhard, F., Magdaleno, F., Klein, S., Trebicka, J., marrech 2017. Department of internal medicine I., University of bonn, germany.am j *physiol gastrointesst liver physiol* 312:G407-G412, 2017,
- Sherlock, S., Dooley, JD. 2002. Hepatic Cirrhosis. *In*: S. Sherlock and J. D. Dooley (eds.) *Diseases of the Liver and Biliary System* Eleventh ed.: Blackwell Science.
- Stancu, C., Sima, A. 2001. Statins: Mechanism Of Action And Effects. *J cell Mol Med*. 4(5): 378-87.
- Starr, SP., Raines, D. 2011. Cirrhosis: diagnosis, management, and prevention. *Am Fam Physician*. 84(12): 1353-59.

- Steel DM and Whitehead AS., 1993. The Acute Phase Response. In:Humoral Factor, E Sim (ed) Oxford.IRL Press.1-29
- Thompson, D; Pepys, MB; Wood, SP.1999. "The physiological structure of human C-reactive protein and its complex with phosphocholine". *Structure*. 7 (2): 169–77.
- Trocha, M., Merwid-L, A., Szuba, A., Chlebda, E., Pieoeniewska, M., Sozański, T., *et al.* 2010. Effect of simvastatin on nitric oxide synthases (eNOS, iNOS) and arginine and its derivatives (ADMA, SDMA) in ischemia/reperfusion injury in rat liver. *Pharmacological Reports*. 62: 343-51.
- Tsochatzis, EA., Bosch, J., Burroughs, AK. 2014. Liver cirrhosis. *The Lancet*. 383: 1749-61.
- Turgeon, ML., 2003. Immunology and Serology in Laboratorium Medicine Third edition. Missouri : Mosby
- Varghese, JS., Krishnaprasad, K., Upadhuyay, R., Revathy, MS., Jayanthi, V. 2007. Lipoprotein profile in cirrhosis of liver. *Eur J of Gastroenterol and Hep*. 19:521–22.
- Wanless, IR., Wong, F., Blendis, LM., Greig, P., Heathcote, EJ., Levy, G. 1995. Hepatic and portal vein thrombosis in cirrhosis: possible role in development of parenchymal extinction and portal hypertension. *Hepatology*. 21: 1238–47.
- Witztum, J.L. 1996. Drugs Used in tha Treatment of Hyperlipoproteinemias. In: Molinoff, P.B., and Ruddon, R.W. (editor). Goodman & Gilman’s The Pharmacological Basic Of Therapeutics. Edisi 9. *New York : McGraw Hill, Inc.*, 887.
- Young B, Gleeson M, Cripps AW. 1991. C-reactive protein: a critical review. *Pathology*. 23:118–24.
- Zafra, C., Abraldes, JG., Turnes, J., Berzigotti, A., Fernández, M., Garca-Pagán, JC., *et al.* 2004. Simvastatin enhances hepatic nitric oxide production and decreases the hepatic vascular tone in patients with cirrhosis. *Gastroenterology*. 126(3): 749-55.